Article
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes.
Investigational new drugs - 1 Aug 2025
Autio Karen A, Kyriakopoulos Christos E, Palyca Paul, Xiao Han, Emamekhoo Hamid, Danila Daniel, Jan Mehrin, Catharine Victoria, Riedel Elyn, Devitt Michael, Laird A Douglas, Scher Howard I
Abstract excerpt
As monotherapy, PARP inhibitors have little cytotoxic effect in tumors without homologous recombinant repair (HRR) alterations. Supported by preclinical models, we hypothesized that the PARP inhibitor talazoparib in combination with temozolomide chemotherapy could induce DNA damage leading to cell death and tumor response in patients with metastatic castration-resistant prostate cancer (mCRPC) without HRR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.